Prospector
Profile
07.1609
|
| |
| Tissera, Inc. |
NAICS |
541710 |
| 8 Maskit St.
Herzliya, Israel 46733 |
Description |
Biotechnology |
| +972-9-9561151 |
Employees |
3 |
| http://www.tissera.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-1.8650 |
| |
Assets |
(mil) |
1.2830 |
| |
Liability |
(mil) |
0.6870 |
| |
(for the year ended 2007-06-30) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
Kost Forer Gabbay & Kasierer states that certain conditions exists that raise doubts about the ability of Tissera, Inc. to continue as a going concern. The Company has suffered recurring losses from operations and has accumulated deficit of approximately $30.2 million since inception. The Company reported net losses of $1.87 million and $1.72 million for the years ended July 31, 2007 and 2006, respectively.
|
| |
|
Intellectual Property:
The Company entered into a Research and License Agreement with Yeda Research and Development Company Limited, whereby Yeda procures the performance of research at the Weizmann Institute of Science, under the supervision of Professor Yair Reisner of the Department of Immunology. Pursuant to the agreement, Yeda provided the Company with an exclusive worldwide license to develop, manufacture and sell products for solid organ transplantation from embryonic tissue based on research conducted under the supervision of Professor Reisner of the Department of Immunology of the Weizmann Institute of Science. [SEC Filing 10-KSB 10-29-07]
|
| |
|
Description:
The Company is dedicated to the advancement of a new era in tissue transplantation with precursor transplant technology.
|
| |
|
Officers:
Amos Eiran (Chair & Interim CEO); Alex Werber (CFO); Robert Pico (Dir.); Meir Segev (Dir.)
|
| |
|
Auditor:
Kost Forer Gabbay & Kasierer
|
| |
|
Securities:
Common Stock-Symbol TSSR.OB; OTC BB;
45,314,332 common shares outstanding as of October 18, 2007.
|
| |
| |
| |
| return to main page |
